Background: Transcatheter device closure of postmyocardial infarction ventricular septal defect (PMIVSD) is less invasive than surgical repair. However, its feasibility, timing, outcome, and prognostic factors remain unclear. Methods: This was a multicenter, retrospective cohort study. Between February 2012 and July 2015, a total of 10 (8 male and 2 female) patients with PMIVSD undergoing attempted device closure were enrolled retrospectively. The procedures were performed under general anesthesia with fluoroscopic and transesophageal echocardiographic guidance. Results: The patients enrolled in the study were in the age range 50e85 years (median age of 76.5 years). The interval from infarction to device closure ranged from 6e147 days, with the median of 12 days. A total of 13 devices were implanted in 10 patients. There were five Amplatzer muscular ventricular septal defect occluders, four Amplatzer septal occluders, three Amplatzer PMIVSD occluders and one Amplatzer vascular plug II. Complications included transient ventricular tachycardia in three patients, device embolization in one patient, and tracheal bleeding in one patient. No procedure-related death, stroke, or cardiac tamponade was noted. During follow-up, two patients died of heart failure and two patients died of sepsis. Overall, subjects with age ! 80 years, systolic blood pressure 90 mmHg, and procedure time !180 minutes were significant predictor factors for mortality. All patients with the interval of infarction to device closure >12 days survived. Conclusion: Our findings indicate that transcatheter device closure of PMIVSD is technically feasible, safe, and effective to reduce the shunt. The crucial prognostic factors were ascertained to be age ! 80 years, systolic blood pressure 90 mmHg, and procedure time !180 minutes.
Introduction
Post myocardial infarction ventricular septal defect (PMIVSD) usually occurs within the 1 st week following infarction, with an incidence of 0.2e0.34% since the advent of reperfusion therapy. 1, 2 If the defect remains unrepaired, it has a high fatality rate of more than 90%. 1 Surgical repair is suggested by using current guidelines to avoid abrupt cardiovascular collapse; however, such intervention still possesses a Conflicts of interest: The authors declare that they have conflicts of interest related to the subject matter or materials discussed in this article.
high mortality rate of 20e87%. 1,3e7 Furthermore, cardiac surgeons typically prefer to wait at least 2e4 weeks for the firm scar to form over the margins of defect, which allows for better anchoring of suture and patch material. 2, 8 Many patients die during this waiting period prior to surgery. Transcatheter device closure of PMIVSD is less invasive and can decrease the mortality rate to 14.3e42%. 8e13 However, its feasibility, timing, outcome, and prognostic factors remain unclear.
Methods

Study design
This is a multicenter, retrospective, cohort study and conducted in accordance with the Declaration of Helsinki and ethic regulation in our hospital.
14 From February 2012 to July 2015, a total of 10 patients (8 males and 2 females) with PMIVSD undergoing attempted device closure were enrolled retrospectively. Their age range was 50e85 years, with the median of 76.5 years. The interval from infarction to VSD found ranged from 2 to 146 days, with the median of 7.5 days. The interval from infarction to device closure ranged from 6 to 147 days, with the median of 12 days. The demographic data of these patients is summarized in Table 1 . Vasoactiveeinotropic score was calculated for the total equivalent dose of inotrope including dopamine, dobutamine, epinephrine, norepinephrine, and milrinone. 15, 16 The Model of End-Stage Liver Disease Excluding International Normalized Ratior (MELD-XI) score was calculated using creatinine and total bilirubin according to the following formula: 5.11 Â ln (bilirubin mg/dL) þ 11.76 Â ln (creatinine mg/dL) þ 9.44, as an index of multiorgan system dysfunction. 17 
Procedure
Informed consent was obtained from all patients or their family members. The device closure procedure was described in a previous report and briefly as related below. Cefazolin (1 g) was given to the patients as a prophylatic antibiotic. 18, 19 Vascular access was obtained from the right internal jugular vein and the right femoral artery. We performed the procedure under general anesthesia, with fluoroscopic and transesophageal echocardiographic guidance. Routine right and left heart catheterizations were done for the evaluation of pulmonary to system flow ratio (Qp/Qs). A Judkins right catheter was advanced retrogradely to cross the VSD. A 0.035-inch glide wire was advanced through the Judkins catheter into the pulmonary artery or superior vena cava, which was captured with a snare catheter through the jugular vein to establish an arteriovenous loop. A 24-or 34-mm compliant low-pressure sizing balloon (St. Jude Medical) was used to measure the stretched size of VSD and was subsequently exchanged for an appropriate sized delivery sheath. The size selection of deployed device was about 1.5e2 times the size of the stretched balloon. Ultimately, the device selection was based on the size of the device. The priority was the Amplatzer muscular VSD occluder (up to 18 mm), Amplatzer PMIVSD occluder (up to 24 mm, available since November 2013), and then atrial septal occluder (up to 40 mm, if bigger device needed). The Amplatzer vascular plug II was used if the defect was the long-tunnel type. If the left ventriculogram fully opacified the right ventricle after the 1 st device implantation, indicating a large residual shunt, we would subsequently try to deploy a second device. After the procedure, oral aspirin, 100 mg daily, was prescribed for at least 6 months. 
Statistics
We stratified each predictor factor into two groups and used Fisher's exact test to correlate them with mortality.
Results
The results are summarized in Table 2 . A total of 13 devices were successfully implanted in 10 patients (Fig. 1) , and 3 patients received two devices (Fig. 2 ). There were five Amplatzer muscular ventricular septal defect occluders, four Amplatzer septal occluders, three Amplatzer PMIVSD occluders, and one Amplatzer vascular plug II. Three patients experienced transient ventricular tachycardia when the sheath crossed the VSD. In Patient 7, the 2 nd device (16-mm Amplatzer muscular VSD occluder) was embolized into the pulmonary artery, which was successfully retrieved and replaced with a 30-mm Amplatzer septal occluder. Patient 2 had a large residual shunt with a sign of heart failure and underwent surgical repair 38 days later. Patient 1 exhibited bleeding from the endotracheal tube which was resolved by reversing the anticoagulation effect of heparin by protamine. There was no cardiac tamponade or stroke. During follow-up, two patients died of heart failure and another two died of pneumonia-associated sepsis. There was no late complication after the procedure. Five patients had good prognosis with New York Heart Association functional class II. Prediction of mortality of different factors is summarized in Table 3 .
Discussion
The main findings of our study include the following. First, transcatheter device closure of PMIVSD is technically feasible. All patients received device implantation successfully. Second, the device closure procedure is safe without major complications of procedure-related death, stroke, or cardiac tamponade. Third, only one patient had a large residual shunt, thereby proving that the procedure can effectively reduce the shunt. Fourth, all patients with systolic blood pressure & 90 mmHg prior to procedure died. All patients with systolic blood pressure > 90 mmHg survived. It indicates that blood pressure is a crucial prognostic factor ( p ¼ 0.005). Fifth, all patients with the interval of infarction to device closure >12 days survived. However, for patients with an interval &12 days, the mortality rate was high (67%). This indicates that intervention at the acute stage carries a high risk. Some cardiologists suggest that it is necessary to delay device closure for > 2 weeks after infarction. 20 In our opinion, this does not mean that early intervention should be avoided because device closure could be a salvage procedure for acute critical patients. Sixth, patients aged ! 80 years have a higher mortality rate than those aged < 80 years (100% vs. 14%, p ¼ 0.033). Seventh, procedure time ! 180 minutes had a higher mortality rate than procedure times < 180 minutes (75% vs. 20%, p ¼ 0.048).
Most prognostic factors are not statistically significant probably because the sample size was quite small. However, the mortality rate of MELD-XI score ! 20 was 60% and < 20 was 20%. The result was similar to those in Assenza et al, indicating that the mortality rate of MELD-XI score ! 20 was 62%. 13 PMIVSDs are often serpiginous and multiple, and balloon sizing can determine the exact size and shape of VSD, which are important for device selection and deployment. 11 About half (26/53) of the patients in the UK registry received balloon sizing. 11 We prefer to use balloon sizing to measure the accurate size of VSD; a compliant low-pressure balloon is recommended to avoid an enlarged VSD. The size selection of the deployed device could be 1.5 times the stretched balloon size in subacute stage. However, it should be at least 1.5e2 times in the acute stage due to the fragile injured myocardium. This study does have certain limitations. First, it was retrospective in nature, with a small sample size. With the progression and broader availability of percutaneous coronary intervention, the incidence of PMIVSD is now quite rare. In fact, it is difficult to perform a randomized comparison with surgical repair.
In conclusion, according to our experience in this study, transcatheter device closure of PMIVSD is technically feasible, safe, and effective to reduce the shunt. We found that patients with age ! 80 years, systolic blood pressure 90 mmHg, and procedure time !180 minutes were significant predictor factors for mortality. 
